A Phase 4 interventional study of TRYPTYR (Acoltremon ophthalmic solution 0.003%) in Dry Eye Disease (DED), sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing acoltremon in Dry Eye Syndromes — 9 open to participants now, 9 under way, none of them phase 3. acoltremon · Dry Eye Syndromes.
Among the 17 studies testing acoltremon in Dry Eye Syndromes, this one is the 12th largest by planned enrollment, is one of 5 that started in 2026, is one of 9 in phase 4, and was the 13th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →9 of the 17 studies testing acoltremon in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Southern College of Optometry · Sites in United States
Ages 18–75
University of California, Berkeley · Sites in United States
Ages 18+
Southern College of Optometry · Sites in United States
Ages 18+
Eye Research Associates, LLC
Ages 18+
University of South Florida · Sites in United States
Ages 18+
By country, each count listing its studies:
acoltremon: first FDA approval 2025 (TRYPTYR). What it is approved for, and how studies give it, is on its page →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 9
First in 2017; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 50 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 17 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 9 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
6 of the studies testing acoltremon in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07848373Eye Research Associates, LLCContact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003% | 2027-02-14 |
| NCT07732010NYU Langone HealthTRYPTYR as a Treatment for Patients With Dry Eye Disease (DED) | 2027-04-20 |
| NCT07888452University of California, BerkeleyCooling Eyedrops for Dry Eye | 2027-05 |
| NCT07849803University of South FloridaEffect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies testing acoltremon in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with the TRYPTYR drug for one month
Drug: TRYPTYR (Acoltremon ophthalmic solution 0.003%)
TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.
Change in ocular surface disease index (OSDI) Score
The Ocular Surface Disease Index (OSDI) is a 12-question screening tool used to measure the severity of dry eye disease and how it affects vision. Scores range from 0 to 100, with higher numbers indicating more severe symptoms.
Time frame: Baseline, Week 2
Change in National Eye Institute (NEI) scale of the cornea
The NEI scale of the cornea is a standardized system used to grade corneal fluorescein staining. It evaluates punctate epithelial erosions (staining) across five specific corneal zones (superior, inferior, nasal, temporal, and central) to yield a total severity score. Each of the 5 zones is graded on an integer scale from 0 (No staining) to 3 (Severe or confluent staining). Total scores of 0-5 typically indicate mild surface disease, 6-10 represent moderate disease, and 11-15 indicate severe ocular surface disease.
Time frame: Baseline, 1 Month
Change in NEI scale of the conjunctiva
The National Eye Institute (NEI) scale of the conjunctiva evaluates the ocular surface by dividing the conjunctiva into six specific areas for evaluation to grade staining. Each of these six regions is graded individually on a 0 (none) to 3 (severe) scale. By adding the scores of all six regions, the conjunctiva yields a total score ranging from 0 to 18. Low scores represent a healthy or mildly compromised ocular surface, whereas high scores indicate severe surface disease like dry eye
Time frame: Baseline, 1 Month
Plan to share: No — he de-identified participant data from the final research dataset will not be shared. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.
Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 9 months is below that.
Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoltremon